Expanding the Curative Potential of CAR T-Cell Therapy

Lymphoma

T-ICAHT: Grading and Prognostic Impact of Thrombocytopenia After CAR T-cell Therapy

Blood

Rejeski K, Sanz J, Fei T, Nair MS, Hashmi H, Avigdor A, Beyar-Katz O, Bücklein VL, Curran KJ, Einarsdottir S, Esensten JH, Glaubach N Dr, Golan-Accav N, Gomez-Llobell M, Halamis I, Itzhaki O, Locke FL, Mailankody S, Marcus R, Maus MV, Palomba ML, Park JH, Pasquini MC, Raj SS, Rajeeve S, Salles GA, Scordo M, Shah GL, Shimoni A, Subklewe M, Tix T, Usmani SZ, Valid OB, Valtis YK, Zuckerman T, Shah NN, Perales MA, Shouval R

doi: 10.1182/blood.2025028833

Lymphoma

Chimeric antigen receptor copies in cell-free DNA predict relapse in aggressive B-cell lymphoma patients treated with CAR T-cell therapy

Br J Haematol

de la Iglesia-San Sebastián I, López-Esteban M, Bastos-Oreiro M, Fernández de Córdoba-Oñate S, Gutierrez M, Carbonell D, Bailén R, Gómez-Centurión I, Fernández-Caldas P, Castilla L, Anguita J, Kwon M, García-Sanz R, Buño I, Martínez-Laperche C

doi: 10.1111/bjh.19916

Lymphoma

Sarcopenia and Skeletal Muscle Loss after CAR T-cell Therapy in Diffuse Large B cell Lymphoma

Clin Cancer Res

Jhaveri K, Thapa R, Ercan D, Saha A, Noble J, Singh P, Fahrmann J, Saini N, Wu R, Dennison JB, Hanash S, Jenq RR, Modi K, Figura N, Chavez J, Shah B, Nishihori T, Lazaryan A, Khimani F, Bachmeier C, Gage K, Mishra A, Perna F, Davila ML, Spiegel J, Rejeski K, Subklewe M, Locke FL, Freeman C, Parker N, Jain MD

doi: 10.1158/1078-0432.CCR-24-3782

Lymphoma

Risk factors for CAR T-cell manufacturing failure and patient outcomes in large B-cell lymphoma: a report from the UK National CAR T Panel

Blood Cancer J

Dulobdas V, Kirkwood AA, Serpenti F, Gautama B, Panopoulou A, Mathew A, Gabriel S, Malladi R, Pealing J, Bonney D, Nicholson E, Besley C, Ghorashian S, Kuhnl A, Davies E, Chappell J, Black A, Menne T, O'Reilly MA, Sanderson R, Chaganti S

doi: 10.1038/s41408-025-01225-9

Lymphoma

CAR T-cell therapy response varies by extranodal disease site in large B-cell lymphoma

Blood Cancer J

Luna A, Devlin SM, Rejeski K, Flynn JR, Corona M, Luttwak E, Rivas-Delgado A, Landego I, Cassanello G, Gomez-Llobell M, Raj SS, Dahi PB, Lin RJ, Parascondola A, Palomba ML, Shah GL, Scordo M, Alarcon Tomas A, Leithner D, Bedmutha A, Schöder H, Imber BS, Salles G, Park JH, Perales MA, Shouval R

doi: 10.1038/s41408-025-01273-1

Lymphoma

Outcomes with loncastuximab tesirine following CAR T-cell therapy in patients with relapsed or refractory diffuse large B-cell lymphoma

Blood Cancer J

Epperla N, Lucero M, Bailey T, Mirams L, Cheung J, Amet M, Milligan G, Chen L

doi: 10.1038/s41408-024-01195-4

ASH 2024

Lymphoma

A novel bicistronic CD19/CD22 CAR T-cell therapy is effective and safe in children with relapsed or refractory B-ALL

Multiple Myeloma (MM)

CAR+ T-Cell Lymphoma after Cilta-cel Therapy for Relapsed or Refractory Myeloma

N Engl J Med

Harrison SJ, Touzeau C, Kint N, Li K, Nguyen T, Mayeur-Rousse C, Rahman M, Le Bris Y, Er J, Eugene-Lamer J, Haynes NM, Li J, Abbott RC, Bodet-Milin C, Moreau A, Letouzé E, Lendvai N, Schecter JM, Deraedt W, Banerjee A, Lengil T, Vogel M, Foulk B, Zhao H, Smirnov D, Slaughter A, Lonardi C, Lee E, Marquez L, Sankari A, Plaks V, Filho JOC, Patel N, Geng D, Gastinne T, Kelly H, Tiong IS, Eveillard M, Chevallier P, Lade S, Moreau P, Grimmond S, Oliaro J, Tessoulin B, Blombery P

doi: 10.1056/NEJMoa2309728

Lymphoma

Related content

T-ICAHT: Grading and Prognostic Impact of Thrombocytopenia After CAR T-cell Therapy

Chimeric antigen receptor copies in cell-free DNA predict relapse in aggressive B-cell lymphoma patients treated with CAR T-cell therapy

Sarcopenia and Skeletal Muscle Loss after CAR T-cell Therapy in Diffuse Large B cell Lymphoma

Risk factors for CAR T-cell manufacturing failure and patient outcomes in large B-cell lymphoma: a report from the UK National CAR T Panel

CAR T-cell therapy response varies by extranodal disease site in large B-cell lymphoma

Outcomes with loncastuximab tesirine following CAR T-cell therapy in patients with relapsed or refractory diffuse large B-cell lymphoma

A novel bicistronic CD19/CD22 CAR T-cell therapy is effective and safe in children with relapsed or refractory B-ALL

CAR+ T-Cell Lymphoma after Cilta-cel Therapy for Relapsed or Refractory Myeloma

Updated Insights from Matching-Adjusted Indirect Comparisons of Two CAR T-cell Therapies in Second-Line Treatment of R/R LBCL